DNA Script completed the $89m Series B funding round.

Danaher Corporation, Agilent Technologies, Life Sciences Partners, Casdin Capital, Illumina Ventures, Bpifrance and Merck Ventures invested $89m Series B funding round in DNA Script, a biotechnology company. “The SYNTAX EDS system was inspired by the wide availability of in-lab and benchtop next-generation sequencing systems and the impact they have had on genomics research and personalized medicine. This first-of-its-kind DNA printer makes writing DNA as simple and straightforward as reading DNA is currently, meaning that research and clinical labs will be able to do same-day synthesis of oligonucleotides, saving precious time when it comes to iterating experiments or developing diagnostic or confirmatory tools," Thomas Ybert, DNA Script CEO and Co-Founder.